Eloralintide
A selective, long-acting amylin receptor agonist with early human weight-management data.
Evidence-led profile
Research snapshot
- Evidence stage
- Investigational; phase 1 human obesity research
- References
- 1 linked sources
- Research coverage
- 1 area
- Editorial review
- Sep 30, 2026
Published by the PepGuide Editorial Team using our research methodology.
Overview
In a 100-participant phase 1 proof-of-concept study, least-squares mean weight reductions across active cohorts ranged from 2.6% to 11.3% at 12 weeks. Cohorts differed in regimen, so the range is not a single treatment effect. The study reported nausea in 8% of exposed participants; it did not compare tolerability directly with GLP-1 drugs.
Research
Phase 1 human study
A 100-participant randomized study reported 2.6%–11.3% least-squares mean weight reductions across active cohorts at week 12. The cohort range is exploratory and should not be compared directly with separate longer trials. Original report.
Safety and Limitations
Phase 1 data are insufficient for rare or long-term harms and cannot support claims of superior tolerability. Eloralintide had no FDA-approved U.S. product identified at this review.
Mechanism of Action
Selective agonism of the amylin receptor, an appetite and energy-intake pathway distinct from direct GLP-1 receptor agonism.
References (1)
Continue researching Eloralintide
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.